"Promising Alzheimer's Drug Sparks Optimism and Uncertainty"

The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer's and mild cognitive impairment, and Medicare has agreed to cover the therapy. Medical centers are working to establish policies and procedures for providing the medication to patients, potentially by the end of summer or early autumn. While there is hope for families and other promising therapies, medical providers remain cautious, recognizing that this is just the first step in developing treatments for complex neurodegenerative diseases.